Xenon Pharmaceuticals Inc. XENE
0 trading plans running, 15 Form 144 notices for $22.0M
10-Q, 10-K and Form 144What XENE's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Aug 15, 2025 to Nov 16, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in |
|---|---|---|---|
| Andrea DiFabio Chief Legal Officer |
Adopted 10b5-1 plan | Jun 30, 2026 | 10-Q Aug 6, 2026 |
| Ian Mortimer President and Chief Executive Officer and a member of the Board of Directors |
Ended 10b5-1 plan | Jun 30, 2026 | 10-Q Nov 12, 2024 |
| Dr. Christopher Kenney Chief Medical Officer |
Adopted 10b5-1 plan | May 29, 2026 | 10-Q Aug 6, 2026 |
| Andrea DiFabio Chief Legal Officer and Corporate Secretary |
Adopted 10b5-1 plan | Dec 3, 2025 | 10-K Feb 26, 2026 |
| Christopher Kenney Chief Medical Officer |
Adopted 10b5-1 plan | Dec 3, 2025 | 10-K Feb 26, 2026 |
| Darren Cline Chief Commercial Officer |
Adopted 10b5-1 plan | Dec 3, 2025 | 10-K Feb 26, 2026 |
| Ian Mortimer President and Chief Executive Officer |
Adopted 10b5-1 plan | Dec 3, 2025 | 10-K Feb 26, 2026 |
| Thomas P. Kelly Chief Financial Officer |
Adopted 10b5-1 plan | Dec 3, 2025 | 10-K Feb 26, 2026 |
| Dr. Gary Patou Board of Directors |
Adopted 10b5-1 plan | Aug 17, 2025 | 10-Q Nov 3, 2025 |
| Dr. Gillian Cannon Board of Directors |
Adopted 10b5-1 plan | Aug 15, 2025 | 10-Q Nov 3, 2025 |
| Ian Mortimer President and Chief Executive Officer |
Adopted plan | – | 10-Q Nov 9, 2026 |
| Thomas P. Kelly Chief Financial Officer |
Adopted plan | – | 10-Q Nov 9, 2026 |
Show the other 4 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Aug 28, 2026 | CHRISTOPHER KENNEY Officer |
7,068 | $438K |
| Aug 13, 2026 | STEVEN GANNON Director |
10,000 | $641K |
| Jun 5, 2026 | GILLIAN CANNON Director |
1,190 | $63K |
| Jun 5, 2026 | GARY PATOU Director |
1,322 | $70K |
| Mar 13, 2026 | CHRISTOPHER JOHN KENNEY Officer |
1,410 | $78K |
| Mar 13, 2026 | ANDREA DIFABIO Officer |
1,342 | $74K |
| Mar 13, 2026 | IAN MORTIMER Officer, Director |
7,308 | $404K |
| Mar 10, 2026 | ANDREA DIFABIO Officer |
2,607 | $157K |
| Mar 10, 2026 | CHRISTOPHER JOHN KENNEY Officer |
2,771 | $167K |
| Mar 10, 2026 | IAN MORTIMER Officer, Director |
11,269 | $677K |
| Mar 9, 2026 | IAN MORTIMER Officer, Director |
270,000 | $16.3M |
| Jan 2, 2026 | IAN MORTIMER Officer, Director |
40,000 | $1.8M |
| Dec 8, 2025 | IAN MORTIMER Officer, Director |
10,830 | $495K |
| Dec 5, 2025 | IAN MORTIMER Officer, Director |
14,375 | $647K |
| Dec 1, 2025 | IAN MORTIMER Officer, Director |
97 | $4K |
Show the other 7 notices
From the Form 144 XML filed with the SEC, since Dec 1, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XENE/export.csv") into a cell.